BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33064728)

  • 1. Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia.
    Krismawati H; Irwanto A; Pongtiku A; Irwan ID; Maladan Y; Sitanggang YA; Wahyuni T; Tanjung R; Sun Y; Liu H; Zhang F; Oktavian A; Liu J
    PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008746. PubMed ID: 33064728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy.
    Liu H; Wang Z; Bao F; Wang C; Sun L; Zhang H; Yu G; Mi Z; Li J; Li L; Zhao Q; Yue Z; Zhao W; Yu W; Cao J; Xiong F; Wang Y; Chai Z; Cheng X; Zhang Y; Fu F; Lang X; Wang X; Irwanto A; Krismawati H; Fu X; Sun Y; You J; Liu J; Pan Q; Chu T; Liu D; Chen S; Shen J; Yan L; Zhang G; Liu J; Zhang F; ; Xiong L; Yang J; Li J; Ke W; Li M; Ning Y; Xiong J; Li M; Xiong M; Yang B; Duan Q; Wang H; Li W; Kuang Y; Li J; Wang L; Cao Q; Xiao P; Xiao B; Zhang L; Lin Z; Wang Y; Shen Y; Yan L; Wu W; Zheng H; Zhan X; Li W; Shang X; Xu Y; Liu Q
    JAMA Dermatol; 2019 Jun; 155(6):666-672. PubMed ID: 30916737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review on Dapsone Hypersensitivity Syndrome Among Chinese Patients with an Emphasis on Preventing Adverse Drug Reactions with Genetic Testing.
    Wang N; Parimi L; Liu H; Zhang F
    Am J Trop Med Hyg; 2017 May; 96(5):1014-1018. PubMed ID: 28167593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of genetic screening test to reduce the incidence of dapsone hypersensitivity syndrome among patients with leprosy in Papua, Indonesia: a study protocol.
    Krismawati H; Ferdiana A; Irwanto A; Budiawan T; Imaniar C; Wahyuni T; Singh P; Mieras L; Pongtiku A
    BMJ Open; 2022 May; 12(5):e057173. PubMed ID: 35545382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses.
    Park HJ; Park JW; Kim SH; Choi SY; Kim HK; Jung CG; Yang MS; Kang DY; Cho MK; Kwon HS; Kang HR; Lee YW;
    Expert Opin Drug Saf; 2020 Oct; 19(10):1349-1356. PubMed ID: 32700588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal.
    Pandey B; Shrestha K; Lewis J; Hawksworth RA; Walker SL
    Trop Doct; 2007 Jul; 37(3):162-3. PubMed ID: 17716505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapsone syndrome with acute renal failure during leprosy treatment: case report.
    Alves-Rodrigues EN; Ribeiro LC; Silva MD; Takiuchi A; Fontes CJ
    Braz J Infect Dis; 2005 Feb; 9(1):84-6. PubMed ID: 15947852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions.
    Chen WT; Wang CW; Lu CW; Chen CB; Lee HE; Hung SI; Choon SE; Yang CH; Liu MT; Chen TJ; Fan WL; Su SC; Lin YY; Chang YC; Chung WH;
    J Invest Dermatol; 2018 Jul; 138(7):1546-1554. PubMed ID: 29458119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapsone hypersensitivity syndrome in an adolescent during treatment during of leprosy.
    Bucaretchi F; Vicente DC; Pereira RM; Tresoldi AT
    Rev Inst Med Trop Sao Paulo; 2004; 46(6):331-4. PubMed ID: 15654479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-B*13:01 and the dapsone hypersensitivity syndrome.
    Zhang FR; Liu H; Irwanto A; Fu XA; Li Y; Yu GQ; Yu YX; Chen MF; Low HQ; Li JH; Bao FF; Foo JN; Bei JX; Jia XM; Liu J; Liany H; Wang N; Niu GY; Wang ZZ; Shi BQ; Tian HQ; Liu HX; Ma SS; Zhou Y; You JB; Yang Q; Wang C; Chu TS; Liu DC; Yu XL; Sun YH; Ning Y; Wei ZH; Chen SL; Chen XC; Zhang ZX; Liu YX; Pulit SL; Wu WB; Zheng ZY; Yang RD; Long H; Liu ZS; Wang JQ; Li M; Zhang LH; Wang H; Wang LM; Xiao P; Li JL; Huang ZM; Huang JX; Li Z; Liu J; Xiong L; Yang J; Wang XD; Yu DB; Lu XM; Zhou GZ; Yan LB; Shen JP; Zhang GC; Zeng YX; de Bakker PI; Chen SM; Liu JJ
    N Engl J Med; 2013 Oct; 369(17):1620-8. PubMed ID: 24152261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapsone hypersensitivity syndrome among leprosy patients in China.
    Tian W; Shen J; Zhou M; Yan L; Zhang G
    Lepr Rev; 2012 Dec; 83(4):370-7. PubMed ID: 23614255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increase in the incidence of dapsone hypersensitivity syndrome--an appraisal.
    Rao PN; Lakshmi TS
    Lepr Rev; 2001 Mar; 72(1):57-62. PubMed ID: 11355519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapsone hypersensitivity syndrome in a lepromatous leprosy patient--A Case Report.
    Gavilanes MC; Palacio AL; Chellini PR; Nery JA; Rego JG
    Lepr Rev; 2015 Jun; 86(2):186-90. PubMed ID: 26502691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan.
    Sheen YS; Chu CY; Wang SH; Tsai TF
    J Dermatolog Treat; 2009; 20(6):340-3. PubMed ID: 19954390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A docking model of dapsone bound to HLA-B*13:01 explains the risk of dapsone hypersensitivity syndrome.
    Watanabe H; Watanabe Y; Tashiro Y; Mushiroda T; Ozeki T; Hashizume H; Sueki H; Yamamoto T; Utsunomiya-Tate N; Gouda H; Kusakabe Y
    J Dermatol Sci; 2017 Dec; 88(3):320-329. PubMed ID: 28870516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
    Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
    An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
    Deps P; Guerra P; Nasser S; Simon M
    Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal hypersensitivity vasculitis associated with dapsone.
    Alves-Rodrigues EN; Ribeiro LC; Silva MD; Takiuchi A; Rabel-Filho OC; Martini-Filho D; Fontes CJ
    Am J Kidney Dis; 2005 Oct; 46(4):e51-3. PubMed ID: 16183407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
    Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
    Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.